Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

855
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
855
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.0K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.5K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.5K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.5K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
Seizures: Classification01:13

Seizures: Classification

1.8K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Melatonin promotes recovery from ischemic stroke by modulating microglia polarization and inhibiting oligodendrocyte pyroptosis via the RORα/AMPKα/STAT1 pathway.

Journal of translational medicine·2026
Same author

LINC01929 promotes breast cancer progression through a TFRC-associated ferroptosis pathway.

Cell death discovery·2026
Same author

GHF-ACL: A novel contrastive learning framework with multi-order graph structures for herb-disease association prediction.

PLoS computational biology·2026
Same author

TCRBinder: Unified pre-trained language model with paired-chain synergy for predicting T-cell receptor binding specificity.

PLoS computational biology·2026
Same author

GMHAN: a heterogeneous graph attention framework for prioritizing coding and non-coding driver genes.

Bioinformatics (Oxford, England)·2026
Same author

SINTER3D: continuous 3D reconstruction of spatial transcriptomics via implicit neural representations.

Genome biology·2026

Related Experiment Video

Updated: Feb 27, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.6K

Intravenous immunoglobulins for epilepsy.

JinSong Geng1, JianCheng Dong, Youping Li

  • 1Evidence-based Medicine Center, Medical School of Nantong University, 19 Qixiu Road, Medical School of Nantong, Nantong, Jiangsu, China, 226001.

The Cochrane Database of Systematic Reviews
|July 5, 2017
PubMed
Summary

Intravenous immunoglobulin (IVIg) showed no significant difference compared to placebo for reducing seizure frequency in epilepsy. Further research is needed to determine IVIg

More Related Videos

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.7K
A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus
05:33

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

Published on: June 23, 2022

3.5K

Related Experiment Videos

Last Updated: Feb 27, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.6K
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.7K
A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus
05:33

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

Published on: June 23, 2022

3.5K

Area of Science:

  • Neurology
  • Immunology

Background:

  • Epilepsy is a common neurological disorder.
  • Immunological abnormalities are observed in some individuals with epilepsy.
  • Intravenous immunoglobulin (IVIg) is a potential treatment approach.

Purpose of the Study:

  • To evaluate the efficacy of IVIg in managing epilepsy.
  • To assess IVIg's impact on seizure frequency, duration, quality of life, and adverse effects.
  • To determine if IVIg is effective as monotherapy or add-on treatment.

Main Methods:

  • Systematic review of randomized or quasi-randomized controlled trials.
  • Searched multiple databases including Cochrane, MEDLINE, and Web of Science up to February 2017.
  • Included one multi-center, double-blind, placebo-controlled trial with 61 participants.

Main Results:

  • No significant difference in seizure frequency reduction between IVIg and placebo.
  • A statistically significant global assessment favored IVIg.
  • No adverse effects were reported; however, the study had a low/unclear risk of bias and low-quality evidence.

Conclusions:

  • Current evidence is insufficient to reliably conclude on the efficacy of IVIg for epilepsy treatment.
  • More high-quality randomized controlled trials are necessary.
  • IVIg monotherapy for epilepsy has not been investigated in randomized controlled trials.